By Zacks Investment Research : Biotechnology was full of success stories in 2013. And some of those stories just got more exciting in February as the Nasdaq Biotech Index ( IBB ) rallied 13% off the lows. My FTM Portfolio also surged higher on the back of names like Pharmacyclics ( PCYC ), ...
could see the sector slumping up to 40%. His favorites to own are Celgene ( CELG ) and Gilead ( GILD ) because of strong cash flows and very low relative multiples. Related ETFs: IBB , XBI , BIB , BBH , FBT , PBE , BIS Post your comment!
By Nathan Gantz : Introduction Alice v. CLS Bank is a lawsuit resolving software patent claims, to be heard by the Supreme Court. This "software patent case" is also a biotech case, due to the fundamental patentability issues under contention. Binary stock displacements should eventuate from the ...
By AllianceBernstein : By Dan Roarty and Edward Bryan As the Olympic Games in Sochi draw to a close, a new era for international sports may be beginning. Uzbekistan last month revealed a program to test children’s genes to predict their athletic potential. With genomics becoming more mainstream, we
By Cam Hui : The biotechnology sector has been on a tear for the past few years. A glance at the biotech ETF ( IBB ) shows that this group (bottom panel) has been steadily advancing since the stock market bottomed in 2009. It decisively broke out to new all-time highs in late 2010. By contrast, the
By John Dowdee : As the 78 million baby boomers reach retirement age, they will place increased demand on the healthcare system. The general consensus is that the aging population will bode well for the healthcare stocks, since a majority of medical costs occur after a person retires. In ...
By Mitchell Clark The last time we looked at Alexion Pharmaceuticals, Inc. ( ALXN ), the position was trading around $121.00 a share. Now, it's $175.00 a share, and once again, the company reported outstanding financial results from its "Soliris" wonder-drug. This stock has been a powerhouse wealth
for healthcare names, with XLV up 47% vs. XLP up 21.3% since the start of 2013. Related ETFs: IYH , IBB , XLV , XLP , XBI , VHT , BIB , PJP , BBH , VDC , FBT , XPH , CURE , PBE , IHE , FXH , RXL , IRY , IXJ , IHI , PPH , IHF , PSCH , XHS , FHLC
should help with trading liquidity. The market may already be stretched - of 14 companies listing so far this year, six are currently below their IPO price. Biotech ETFs: IBB , XBI , BIB , BBH , FBT , PBE , BIS Post your comment!
Biotechnology Fund (FBIOX) is still up 9.3% YTD beating the largest ETF ( IBB ) by 3 percentage pts. The mid and small cap weighted XBI ($145.50) is up 11.76% YTD but off its 52 week (January 2014) high of $161.55. Some of the holdings of this ETF